MedPage Today news story
No women taking long-acting cabotegravir (Apretude) for HIV PrEP developed an HIV infection despite short delays before some maintenance injections, according to a US study of routine clinical care.
There were no cases of incident HIV over a median follow-up of 13 months among 315 women who started cabotegravir in 2021-2024 as part of the OPERA longitudinal cohort.
Read the full news story here.
SEE ALSO:
Source : MedPage Today
Related HIV and Co-Infections News
-
[AIDS 2026] Africa Health Research Institute: Mobile Men study: injectable PrEP beats pills for men who travel for work
-
[AIDS 2026] MedPage Today: Long-acting lenacapavir still delivered effective HIV PrEP after a year
-
[AIDS 2026] Managed Healthcare Executive: Community-led chemsex harm reduction programs boost HIV retention in South Africa, other countries
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.